QLGN מכפיל מחיר להכנסות עתידי Qualigen

Qualigen Therapeutics develops diagnostics and therapies to combat oncology and viruses, targeting global laboratory demand. The company's revenues are based on the sale of test systems, while future success depends on pharmaceutical developments. This GURU.Markets chart for the forward P/S ratio reflects a trend where 1.50 captures a new level. Optimized supply chains and insurance reserves guarantee logistical stability.

To assess the credit quality of Qualigen Therapeutics (QLGN), the analyst utilizes the company's forward P/S chart, which compares current market capitalization with expected revenue to identify whether the asset is overvalued or undervalued. The stability of this metric is supported by a clinical test outsourcing model coupled with full patent ownership, which reduces operational risks and allows the compression of the multiple to be interpreted as a signal to revise the investment risk profile.